β-Nicotinamide Mononucleotide Monoclonal antibody

β-Nicotinamide Mononucleotide Monoclonal Antibody for ELISA
Cat No. 68638-1-Ig

产品说明书

CloneNo. 3A1F11

宿主/亚型

Mouse / IgG1

种属反应性

chemical compound

应用

ELISA

β-NMN, β NMN, NMN

缓冲液配方:  PBS and Azide
PBS and Azide
PBS Only
偶联物:  Unconjugated
Unconjugated
规格: 

-/ -


经过测试的应用

Positive ELISA detected inβ-Nicotinamide Mononucleotide, urine

推荐稀释比

应用推荐稀释比
Enzyme-linked Immunosorbent Assay (ELISA)ELISA : 1:2000-1:20000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

68638-1-Ig targets β-Nicotinamide Mononucleotide in ELISA applications and shows reactivity with chemical compound samples.

经测试应用 ELISA Application Description
经测试反应性 chemical compound
免疫原 PTG 种属同源性预测
宿主/亚型 Mouse / IgG1
抗体类别 Monoclonal
产品类型 Antibody
全称 β-Nicotinamide Mononucleotide
别名 β-NMN, β NMN, NMN
基因名称
Gene ID (NCBI)
RRIDAB_3085327
偶联类型 Unconjugated
形式 Liquid
纯化方式Protein G purification
储存缓冲液 PBS with 0.02% sodium azide and 50% glycerol , pH 7.3
储存条件Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

Nicotinamide mononucleotide ("NMN" and "β-NMN") is a nucleotide derived from ribose, nicotinamide, nicotinamide riboside and niacin. In humans, several enzymes use NMN to generate nicotinamide adenine dinucleotide (NADH). In mice, it has been proposed that NMN is absorbed via the small intestine within 10 minutes of oral uptake and converted to nicotinamide adenine dinucleotide (NAD+) through the Slc12a8 transporter. However, this observation has been challenged, and the matter remains unsettled. Maintain cell quality and reduce cell aging with β-nicotinamide mononucleotide (β-NMN), an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD+) (Bogan & Brenner). β-NMN is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and is converted to NAD+ by nicotinamide-nucleotide adenylyltransferase.

Loading...